Clinical trial readout dates for Biogen Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 Nusinersen Muscular Atrophy, Spinal · NCT04729907 | July 2026 Primary data collected |
| Phase 3 Felzartamab Antibody-mediated Rejection · NCT06685757 | December 2026 Ongoing |
| Phase 3 BIIB017 (peginterferon beta-1a) Multiple Sclerosis, Relapsing-Remitting · NCT03958877 | May 2027 Ongoing |
| Phase 3 Felzartamab Immunoglobulin A Nephropathy (IgAN) · NCT06935357 | May 2027 Recruiting |
| Phase 3 Tofersen Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation · NCT04856982 | August 2027 Ongoing |
| Phase 3 Nusinersen Spinal Muscular Atrophy · NCT05067790 | September 2027 Ongoing |
| Phase 3 Omaveloxolone Friedreich Ataxia · NCT06953583 | November 2027 Ongoing |
| Phase 2 Felzartamab Graves' Disease · NCT07722546 | January 2028 Recruiting |
| Phase 2 Felzartamab Microvascular Inflammation · NCT07219043 | February 2028 Recruiting |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-28 |